Emergency Medicine · Vol. 1, No. 2 · 2015 · pp. 22–30 · e-ISSN 2379-4046

Stevens-Johnson Syndrome without Skin Lesions: A Rare and Clinically Challenging Disease in the Urgent Setting

Ursula M. Anders, Elise J. Taylor, Victoria Kravchuk, Joseph R. Martel, James B. Martel

Research Department, Martel Eye Medical Group, 11216 Trinity River Drive, Rancho Cor- dova, 95670 CA, USAUnited States
Research Department, Martel Eye Medical Group, 11216 Trinity River Drive, Rancho Cor- dova, 95670 CA, USA; Graduate Medical Education, California Northstate University College of Medicine, 9700 West Taron Drive, Elk Grove, 95757 CA, USA; Department of Ophthalmology, Dignity Health, 6501 Coyle Avenue, Carmichael, 95608 CA USA

DOI: https://doi.org/10.17140/emoj-1-106 · Published 2015-05-22 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2015 The Author(s)

Abstract

Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme are life threatening diseases causing mucocutaneous eruptions and can be difficult to manage medically. When oral tissues are involved, airway management can be of critical importance. Fluid and electrolyte imbalance are common and protocols to prevent secondary infection are initiated. All three conditions are rapidly evolving. Stevens-Johnson syndrome is more commonly associated with Mycoplasma pneumoniae in the pediatric population and drug hypersensitivity in adults, whereas erythema multiforme is mostly associated with herpes simplex virus in the adult population. These diseases are T-cell-mediated immune reactions, thought to represent a spectrum of the same disease. Clinical and immunohistochemical techniques are capable of differentiating Stevens-Johnson syndrome from erythema multiforme and provide insight into the possible underlying pathology creating the disease. Rare cases of Stevens-Johnson syndrome without skin manifestations have been associated with Mycoplasma pneumoniae and predominantly occur in males. In-hospital management is recommended to provide airway support, maintain fluid intake, electrolyte balance, obtain multi-speciality consultation, and to perform diagnostic testing. We describe a case of a 14 year old male with atypical Stevens-Johnson syndrome and a review of the literature.

Keywords: Stevens-Johnson syndrome; Toxic epidermal necrolysis; Erythema multiforme; Immunohistochemical; Episcleritis; Ulcerative stomatitis; Mycoplasma pneumoniae associated mucositis (MPAM); Fuchs syndrome; Major histocompatibility class; Non-MPAM atypical Stevens-Johnson syndrome

Methods

We performed a systematic electronic literature search using the PubMed and Ovid MEDLINE databases. The last search was performed on April 7, 2015. The keywords used were: atypical Stevens Johnson syndrome, incomplete Stevens- Johnson syndrome, Stevens-Johnson syndrome without skin lesions, Mycoplasma pneumoniae associated mucositis, and Fuchs syndrome. All literature was limited to the English language.

Titles and abstracts were read to determine eligibility. Patients were included if they met the criteria for atypical SJS which included: lesions involving at least two mucous membranes (mouth, ocular, or genital), no skin involvement, and positive infection or suspected drug reaction.

Results

Our search yielded 1,192 publications that included the keywords listed in our methods section. 24 articles met the cri-

including our reported patient. Patients were separated into two categories: children ages 3 to 16 years of age (17 patients, Table 1) and adults 18 to 44 years of age (15 patients, Table 2). Information for each case includes age, sex, chest involvement, genital involvement, etiology, diagnosis, diagnostic testing, and treatment. No patients under the age of 3 or over the age of 44 were reported in the literature.

Of the pediatric cases (Table 1), fifteen patients were male (88%), ten patients had chest involvement (59%), ten patients had genital involvement (59%), and fourteen patients had positive MP infection (82%). One was treated with immunosuppressants, all were treated with antibiotics (mainly macrolides), and one was treated with intravenous immunoglobulins (IVIg). All patients had a favorable outcome and all had complete resolution to their baseline health.

A prior review of atypical SJS by Vujic, et al. in 2014 yielded 818 search results, of which only 11 articles (13 patients) met their criteria.26 The review was limited to adult patients between the ages of 18 to 38 years of age. Ten patients were male (77%), six patients had chest involvement (46%), nine patients had genital involvement (69%), and all patients had positive MP infection (100%). Nine were treated with immunosuppressants and ten were treated with antibiotics, which were mainly macrolides and fluoroquinolones.

For the adult cases, one case was excluded from Vujic, et al. for minimal skin involvement, and three more were included. Of those three additional cases, 2 were male, 2 had chest involvement, none had genital involvement, and two had positive MP infection. All were treated with immunosuppressants, two were treated with antibiotics, and one was treated with IVIg. All patients had a favorable outcome.

Four cases were not associated with MP (Table 1-2).

Of the pediatric cases, one cause was unknown and two were from a suspected drug reaction. The presumed cause in the adult case was from MP despite having negative serological testing, although she did test positive for influenza type B.

Discussion

Erythema Multiforme

EM, SJS, and TEN are acute, immune-mediated, hypersensitivity reactions to certain medications or infections, which are believed to trigger a cytotoxic response. EM was previously thought to be part of the spectrum of SJS and TEN, but today it is recognized as a distinct entity with different clinical and epi- 29,30 demiological characteristics. EM is manifested by characteristically raised, bullous skin lesions that are palpable. Epidermal detachment occurs in less than 10% of the body surface area and there is minimal mucous membrane involvement. Oral lesions are described as polymorphic, erosive, ampullary, and erythema-

29 31 tosus.29 EM occurs mostly in adults between 20 to 40 years old31 3,29,30 and is most often caused by HSV.

Stevens-Johnson Syndrome

SJS was first described in 1922 by Albert Mason Stevens and Frank Chambliss Johnson. It is considered to be a single disease entity with TEN, with less severity. The process begins with fever and flu-like symptoms, followed by a breakout of severe mucosal erosions and diffuse, flat atypical skin lesions that are non-palpable. SJS has a prevalence of 1.2-6 /mil- 4,33 lion cases per year, with a mortality rate of 5-10%. The most commonly identified cause of SJS in children is infection and 28,10,34,35 drug sensitivity for adults. Viral agents associated with SJS include coxsackie virus, HSV, AIDS, influenza, hepatitis, mumps, and Epstein-Barr. Associated bacterial agents include group A beta-hemolytic streptococci, diphtheria, brucellosis, lymphogranuloma venereum, mycobacteria, MP, rickettsia, tularemia, and typhoid.

Atypical Stevens-Johnson Syndrome/Mycoplasma Pneumoni- ae-Associated Mucositis

The first case of atypical SJS was described by Maj Otto 11,19,23 F. Sieber in 1967. Most cases of this disorder have a better prognosis and recovery time than typical SJS, and to date there have been no mortalities from this condition. It is difficult to determine at the onset of this disorder if it will proceed to complete SJS or TEN. Ocular involvement occurs in every case and can include diffuse bullous conjunctival edema, pseudomembranes of the conjunctiva, corneal epithelial defects and episcleritis. In 2005, Schalock and Dinulos proposed that the diagnosis of atypical SJS be classified as Mycoplasma pneumoniae-associated mucositis (MPAM) due to the striking feature that atypical cases of SJS are associated with MP.11 MP is the most common cause of childhood pneumonia and is a self-limiting disease managed without antibiotics, which can explain why there is a better prognosis for MPAM.

In our review of the literature, four atypical cases were not associated with MP, therefore not fitting the criteria for MPAM (Tables 1 and 2). Of the pediatric cases, one cause was unknown and two were from a suspected drug reaction. The adult case was more complicated because the presumed cause was from MP despite having negative serological testing, only because the more likely cause of atypical SJS is from MP. The patient tested positive for influenza type B, which we suspect was the actual triggering factor. This suggests there may be other variant forms of atypical SJS, which we feel is the case for our patient. We suspect our patient developed a reaction to the azithromycin, which similarly occurred after a dose of penicillin three years prior with the exception of the mucosal necrosis. A similar case is described by Lamireau et al., of a 7-year-old boy that initially presented with non-MPAM atypical SJS, which recurred and resulted in a complete SJS.8

Author et al. Age Sex Etiology Diagnosis Treatment*

Alter 13 M N N MP MPAM Erythromycin

10 M Y Y MP MPAM Erythromycin

12 M Y Y MP MPAM Erythromycin

Bressan 9 F N/A Y MP MPAM IVIg

Fearon 8 M Y N MP Agglutination assays Roxithromycin

Lamireau 6 M Y N MP SJS PCR, IgG, - cold

7 M N N

Latsch 13 F Y Y MP Clarithromycin

11 M N N MP Clarithromycin

Meyer Sauteur 7 M Y Y MP Fuchs complement fixation Azithromycin

Ravin 14 M Y Y MP Throat swab PCR

16 M Y Y MP Throat swab PCR

Schalock 17 M N/A N MP MPAM IgG Azithromycin

Strawn 15 M Y Y Drug N/A

Trapp 13 M N/A Y MP MPAM IgM, - cold agglutinin Azithromycin

Vanfleteren 14 M Y Y MP IgG, IgM

Ours 14 M N N

EBV: Epstein Barr Virus; RSV: Respiratory Syncytial Virus. Age, sex, chest involvement, genital involvement, etiology, diagnosis, diagnostic methods, and treatment for 17 pediatric cases of atypical Stevens-Johnson syndrome. *The literature shows a variability in initial treatment, with the ultimate treatment being focused on treating Mycoplasma pneumonia or inflammation which is shown in this table.

Table 1. Pediatric cases of atypical Stevens-Johnson syndrome.

Chest Genital Diagnostic Involved Involved Testing

Complement fixation titer Complement fixation titer Complement fixation titer IgM, agglutination assays MPAM w/ RSV Mouth culture, oral Erythromycin, thalidomide agglutinin Not Rovamycin, pred- SJS Serology, - PCR nisone Stated Throat swab PCR, SJS w/o microparticle aggluskin lesions tination assay, IgM, -IgA, -IgG Sputum specimen, SJS w/o microparticle aggluskin lesions tination assay, IgM, IgA, IgG Throat swab PCR,

titer Atypical Cefuroxime, SJS azithromycin Atypical Ceftriaxone, SJS azithromycin

Atypical Cefdinir, azithro- SJS mycin

Clarithromycin, SJS w/o amoxicillinskin lesions clavulanic acid, acyclovir

Drug SJS w/o IgG, -IgM, - oral PCR, skin lesions w/ EBV NA IgG and CA Doxycycline EBV IgG

Author et al. Age Sex Etiology

Birch 21 F N/A Y MP

Havliza 32 F N/A N MP

38 F N/A N MP

Hillebrand 23 M Y Y MP

Kirke 18 M N Y MP

Li 26 M N Y MP

Majima 44 F Y N

McGouran 18 M N Y MP

Ramasamy 19 M Y N MP

Sieber 22 M Y Y MP

Sternbersky 22 M N/A Y MP

Varghese 20 M Y N MP

Vujic 23 M Y N MP

Walicka 28 M Y Y MP

Yachoui 29 M N/A Y MP Age, sex, chest involvement, genital involvement, etiology, diagnosis, diagnostic methods, shows a variability in initial treatment, with the ultimate treatment being focused on treating Mycoplasma pneumonia or inflammation which is shown in this table.

Table 2. Adult cases of atypical Stevens-Johnson syndrome.

Chest Genital Diagnostic Diagnosis Treatment* Involved Involved Testing

Esophageal biopsy, - PCR, Atypical SJS IVIg, levofloxacin IgM Prenisolone, acy- Fuchs Antibody titers clovir, cefuroxime, levofloxacin Prenisolone, acy- Fuchs Antibody titers clovir, cefuroxime, levofloxacin Amoxicillin- Throat swab PCR, agglutina- Incomplete SJS clavulanic acid, tion IgM IgG titer azithromycin Oral biopsy, - immunofluo- SJS rescence, IgM, complement Prednisolone fixation titer, cold agglutinin Amoxicillin, Oral biopsy, IgM, -cold oseltamivir, meth- Fuchs agglutinin ylprednisolone, clarithromycin Methylpredniso- Presumed SJS-like mu- -IgM, + influenza B from lone, prednisocositis w/o skin nasal swab lone, ampicillin, MP lesions azithromycin Methylpredniso- Atypical SJS IgM lone Complement fixation titer, Co-amoxiclav, Incomplete SJS agglutination assays, convaerythromycin lescent serum sample Throat swab, MP hemaggluti- Prednisone, so- SJS nation-inhibition, complement dium cephalothin, fixation titer tetracycline

Fuchs IgG, IgM Clarithromycin

Levofloxacin, IgG, IgM, immunofluores- clindamycin, IVIg, MPAM cence methylprednisolone Oral mucosa biopsy, IgA, Doxycycline, MPAM IgG, IgM, -immunofluoresprednisolone cence Ceftriaxone, fluconazole, ciprofloxacin, cyclosporine A, Immunoenzymatic examina- SJS fenoterol and iption ratropium bromide (nebulizer), doxycycline, ambroxol, fenoterol Atypical SJS IgM Solumedrol and treatment for 15 adult cases of atypical Stevens-Johnson syndrome. *The literature

To our knowledge, there are only four reports of SJS 35-37 associated with azithromycin, with our case being the first described for atypical SJS. The first reported case describes a 5-year-old boy who developed oral pain and skin eruptions three days after taking azithromycin. Initial HSV testing was unremarkable, but showed an increase in IgM antibody after retesting. They suspected the HSV was reactivated after the use of steroids, which may explain the positivity for Epstein-Barr in our case.

Genetic Predisposition

The underlying root for the spectrum of disease presentation and treatment responses between atypical SJS, MPAM, SJS, TEN and EM may have some underlying genetic influences. A strong genetic association can be formed by examining Human Leukocyte Antigen (HLA) typing, occurrences in family members, and recurrence. HLA-B*5701, HLA-B*5801, HLA- B*1502, HLA-A*3101, HLA-A*0206, HLA-B*4403, HLA- A29, HLA-B12, HLA-DR7, and HLA-A2 are linked to SJS 38-41 drug hypersensitivity reactions. HLA-DQB1*0601, HLA- DQA1*0103, DQB1*0301, and HLA-A*0206 are linked to ocular manifestations in SJS.42 Genetic influences can explain why SJS occurs in multiple family members even though it is a rare condition43 or why it recurs in certain individuals. Finkelstein, et al. reported 55 cases of SJS/TEN, of which 10 were reported to have a recurrence of SJS up to seven years after the initial episode.35 The suspected initial triggers were from medication (5 cases), MP infections (3 cases), HSV infection (1 case), and influenza (1 case). Recurrences were from medication (2 cases), MP infection (4 cases), HSV infection (2 cases), and unknown (2 cases). Three patients had more than two recurrent episodes.

Mechanism

SJS/TEN hypersensitivity reactions are mediated by cytotoxic T lymphocyte and natural killer cell responses resulting in keratinocyte death.44 CD8+ T-cells recognize antigens bound to major histocompatibility complex I molecules, which activates two different types of cytotoxic signals. The first signal releases perforin, granzyme B, and granulysin which go into the cytosol of the target cell to eventually trigger apoptosis. The second signal includes the expression of FAS ligand which binds to FAS molecules on the surface of the target cell, leading to apoptosis. Keratinocyte death causes separation of the epidermis from the dermis, resulting in the blistering and classic skin lesions of typical SJS. This triggers cytokines (TNF-alpha), creating more inflammation and eventual necrosis.

Diagnostic Methods

The diagnosis of MP is demonstrated by immunoglobulin diagnostic work up and PCR. The use of PCR is rapid and enables physicians to quickly diagnose and treat patients, although one case of positive MPAM by IgM and esophageal biopsy de-

sensitivity of PCR ranges from 78-100%, while serology ranges from 50-66%.

Skin biopsies are a definitive way to differentiate SJS/ TEN from EM. Histopathological analyses typically show subepidermal blistering, widespread keratinocyte apoptosis, and full-thickness epidermal necrosis and detachment with a sparse dermal mononuclear infiltrate.44 Differences can also be distinguished in their early stages. The number of granulysin- and perforin-expressing CD8+ cells are greater in SJS than EM, while the number of Foxp3 and CD4+ cells are lower.1 However, this technique is unavailable in atypical cases where there are no skin lesions present. Oral biopsies have been performed for atypical SJS/MPAM, which show highly necrotic mucosa with extensive inflammatory infiltrate consistent with SJS.26

Management and Treatment

There is a complexity of the treatment for a condition which may in the long run be self-limiting, however may evolve due to its complexity. Treatment with antibiotics and immunosuppressive agents remains the mainstay of management for patients with a suspected infectious cause. There are questions about efficacy and safety regarding the use of corticosteroids, however, an improvement in the disease indicates that there is an inflammatory component that needs to be treated. It is common for patients to be treated with an antiviral when there is a suspected viral infection or when being treated with corticosteroids. Patients with suspected adverse reactions to medication must be withdrawn from it. The use of plasmapheresis and hemodialysis to remove these agents is debated.44 Macrolides are commonly used to treat MP infections, however there is an increase in resistance to this class of antibiotics. An estimated resistance rate of 27% was documented in the United States, and reaches up to 90% in China.45 This is particularly challenging for children when there are not as many options for treatment because of potential toxicities.

Other treatments such as IVIg in patients with SJS, TEN, or EM are sometimes used to target Fas/FasL interactions, and are shown to have reduced mortality rates.44 IVIg was used in only one case of atypical SJS which produced a good outcome (Table 2). Additional treatments include Tumor Necrosis Factor-alpha pathway antagonizers (TNF inhibitors, pentoxyfilline, thalidomide, infliximab) and immunomodulators (cyclophosphamide, cyclosporine, N-acetylcysteine, and pentoxyfilline) to reduce the amount of steroids.44 Maintaining airway support and balancing nutritional and fluid intake is also crucial in improving the condition of these patients.

Conclusion

EM, atypical SJS, MPAM, SJS, and TEN are all disorders which change rapidly and may pose life threatening consequences. Despite all therapeutic efforts, the mortality rate is

with any underlying medical condition. Chronic ocular complications and mucosal scarring may persist after treatment. We recommend that all patients with ocular, buccal and genital mucosa erosions have ophthalmologic, ENT and dermatologic consultation. Patients should be admitted in the acute setting, particularly when there are issues of airway integrity. This allows for greater patient stabilization, improved diagnosis, and better multi-specialty team approach to the complex and often unusual patient presentation.

Acknowledgements

The authors report no financial interests or conflicts of interest.

Consent Statement

Consent was obtained by the patients father as patient was a minor.

References

  1. IwaiSSuekiHWatanabeHSasakiYSuzukiTIijimaM. Distinguishing Between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis j.J Dermatol. 2012; 39(9): 781-786. doi: 10.1111/j.1346-8138.2012.01532.x10.1111/j.1346-8138.2012.01532.x https://doi.org/10.1111/j.1346-8138.2012.01532.x
  2. WetterDADavisMD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at mayo clinic, 2000 to 2007. J Am Acad Dermatol. 2010; 62(1): 45-53. doi: 10.1016/j.jaad.2009.06.04610.1016/j.jaad.2009.06.046 https://doi.org/10.1016/j.jaad.2009.06.046
  3. MockenhauptM. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011; 7(6): 803-813. doi: 10.1586/eci.11.6610.1586/eci.11.66 https://doi.org/10.1586/eci.11.66
  4. Latsch K, Girschick HJ, Abele-Horn, M. Stevens-Johnson syndrome without skin lesions: case report. J Med Microbiol. 2007; 56(Pt 12): 1696-1699. doi: 10.1099/jmm.0.47318-0 https://doi.org/10.1099/jmm.0.47318-0
  5. AlterSJStringerB. Mycoplasma pneumoniae infections associated with severe mucositis. Clin Pediatr. 1990; 29(10): 602- 604
  6. BressanSMionTAndreolaBBisognoGDa DaltL. Severe mycoplasma pneumoniae-associated mucositis treated with immunoglobulins. Acta Paediatr. 2011; 100(11): e238-e240. doi: 10.1111/j.1651-2227.2011.02342.x10.1111/j.1651-2227.2011.02342.x https://doi.org/10.1111/j.1651-2227.2011.02342.x
  7. FearonDHeskethELMitchellAEGrimwoodK. Mycoplasma pneumoniae infection complicated by pneumomediastinum and severe mucositis. J Paediatr Child Health. 2007; 43(5): 403-405. doi: 10.1111/j.1440-1754.2007.01088.x10.1111/j.1440-1754.2007.01088.x https://doi.org/10.1111/j.1440-1754.2007.01088.x
  8. LamireauTLeaute-LabrezeCLe BailBTaiebA. Esopha- 2001; 33(6): 550-553. doi: 10.1046/j.1525-1470.2003.03012.x10.1046/j.1525-1470.2003.03012.x https://doi.org/10.1046/j.1525-1470.2003.03012.x
  9. Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis-part of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges. 2012; 10(10): 740- 746. doi: 10.1111/j.1610-0387.2012.07951.x https://doi.org/10.1111/j.1610-0387.2012.07951.x
  10. RavinKARappaportLDZuckerbraunNSWadowskyRMWaldERMichaelsMM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 2007; 119(4): e-1002-e1005. doi: 10.1542/peds.2006-240110.1542/peds.2006-2401 https://doi.org/10.1542/peds.2006-2401
  11. SchalockPCDinulosJG. Mycoplasma pneumoniae-Induced Stevens-Johnson Syndrome without skin lesions: fact or fiction? J Am Acad Dermatol. 2005; 52(2): 312-315. doi: 10.1016/j. jaad.2004.07.04410.1016/j.jaad.2004.07.044 https://doi.org/10.1016/j.jaad.2004.07.044
  12. StrawnJRWhitselRNandagopalJJDelbelloMP. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine. J Child Adolesc Psychopharmacol. 2011; 21(1): 91-92. doi: 10.1089/cap.2010.007110.1089/cap.2010.0071 https://doi.org/10.1089/cap.2010.0071
  13. TrappLWSchrantzSJJoseph-GriffinMAHagemanJRWaskowSE. A 13-year-old boy with pharyngitis, oral ulcers, and dehydration. mycoplasma pneumoniae-associated mucositis. Pediatr Ann. 2013; 42(4): 148-150. doi: 10.3928/00904481- 20130326-0610.3928/00904481-20130326-06 https://doi.org/10.3928/00904481-20130326-06
  14. VanfleterenIGyselDVDe BrandtC. Stevens-Johnson syndrome: a diagnostic challenge in the absence of skin lesions. Pediat Dermatol. 2003; 20(1): 52-56
  15. BirchJChamlinSDuerstRJacobsohnD. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome in a hematopoietic stem cell transplant recipient. Pediatr Blood Cancer. 2008; 50(6): 1278-1279. doi: 10.1002/pbc.2149310.1002/pbc.21493 https://doi.org/10.1002/pbc.21493
  16. HavlizaKJakobARompelR. Erythema multiforme majus (fuchs syndrome) associated with mycoplasma pneumoniae infection in two patients. J Dtsch Dermatol Ges. 2009; 7(5): 445- 448. doi: 10.1111/j.1610-0387.2008.06978.x10.1111/j.1610-0387.2008.06978.x https://doi.org/10.1111/j.1610-0387.2008.06978.x
  17. Hillebrand-Haverkort ME, Budding AE, bij de Vaate LA, van Agtmael MA. Mycoplasma pneumoniae infection with incomplete Stevens-Johnson syndrome. Lancet Infect Dis. 2008; 8(10): 586-587. doi: 10.1016/S1473-3099(08)70209-3 https://doi.org/10.1016/s1473-3099(08)70209-3
  18. KirkeSPowellFC. Mucosal erosions and a cough. Ir Med J. 2003; 96(8): 245
  19. LiKHaberRM. Stevens-Johnson syndrome without skin lesions (fuchs syndrome): a literature review of adult cases with mycoplasma cause. Arch Dermatol. 2012; 148(8): 963-964. doi:
  20. MajimaYIkedaYYagiHEnokidaKMiuraTTokuraY. Colonic involvement in Stevens-Johnson syndrome-like mucositis without skin lesions. Allergol Int. 2015; 64(1): 106-108. doi: 10.1016/j.alit.2014.08.01010.1016/j.alit.2014.08.010 https://doi.org/10.1016/j.alit.2014.08.010
  21. McGouranDCPettersonTMcLarenJMWolbinskiMP. Mucositis, conjunctivitis but no rash- the atypical Stevens-Johnson syndrome. Acute Med. 2011; 10(2): 81-82
  22. RamasamyAPatelCConlonC. Incomplete Stevens-Johnson syndrome secondary to atypical pneumonia. BMJ Case Rep. 2011; 2011. doi: 10.1136/bcr.08.2011.456810.1136/bcr.08.2011.4568 https://doi.org/10.1136/bcr.08.2011.4568
  23. Sieber Of Jr, John TJ, Fulginiti VA, Overholt EC. Stevens-Johnson syndrome associated with mycoplasma pneumoniae infection. JAMA. 1967; 200(1): 79-81
  24. SternberskyJTichyM. Fuchs’ syndrome (Stevens-Johnson syndrome without skin involvement) in an adult male-a case report and general characteristics of the sporadically diagnosed disease. Acta Dermatovenerol Croat. 2014; 22(4): 284-287
  25. VargheseCSharainKSkalskiJRamarK. Mycoplasma pneumonia-associated mucositis. BMJ Case Rep. 2014; 2014
  26. VujicIShroffAGrzelkaM. Mycoplasma pneumoniae-associated mucositis-case report and systematic review of literature. J Eur Acad Dermatol Venerol. 2014; 1-4
  27. WalickaMMajsterekMRakowskaA. Mycoplasma pneumoniae induced pneumonia with Stevens Johnson syndrome of acute atypical course. Pol Arch Med Wewn. 2008; 118(7-8): 449-453. ‐ ‐
  28. Yachoui R, Kolasinski S, Feinstein, D. Mycoplasma pneumoniae with atypical Stevens-Johnson syndrome: a diagnostic challenge. Case Rep Infect Dis. 2013; 2013: 457161. doi: 10.1155/2013/457161 https://doi.org/10.1155/2013/457161
  29. Bascones-MartínezAGarcía-GarcíaVMeurmanJHRequena-CaballeroL. Immune-mediated diseases: what can be found in the oral cavity? Int J Dermatol. 2014. doi: 10.1111/ ijd.12681
  30. SchneiderGKachrooSJonesN. A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens-Johnson syndrome, or toxic epidermal necrolysis using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012; 21(Suppl 1): 236- 239. doi: 10.1002/pds.233110.1002/pds.2331 https://doi.org/10.1002/pds.2331
  31. ScullyCBaganJ. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg. 2008; 46(2): 90-95. doi: 10.1016/j.bjoms.2007.07.20210.1016/j.bjoms.2007.07.202 https://doi.org/10.1016/j.bjoms.2007.07.202
  32. Stevens AM, Johnson, FC. A new eruptive fever associated with stomatitis and ophthalmia report of two cases in children. Am J Dis Child. 1922; 24(6): 526-533. doi: 10.1001/ archpedi.1922.04120120077005
  33. HynesAYKafkalaCDaoudYJFosterCS. Controversy in the use of high-dose systemic steroids in the acute care of patients with Sevens-Johnson syndrome. Int Ophthalmol Clin. 2005; 45(4): 25-48
  34. TayYKHuffJCWestonWL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996; 35(5 Pt 1): 757-760. doi: 10.1016/S0190-9622(96)90732-X10.1016/s0190-9622(96)90732-x https://doi.org/10.1016/s0190-9622(96)90732-x
  35. FinkelsteinYSoonGSAcunaP. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011; 128(4): 723-728. doi: 10.1542/peds.2010-332210.1542/peds.2010-3322 https://doi.org/10.1542/peds.2010-3322
  36. AiharaYItoSKobayashiYAiharaM. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Allergy. 2004; 59(1): 118. doi: 10.1046/j.1398-9995.2003.00336.x10.1046/j.1398-9995.2003.00336.x https://doi.org/10.1046/j.1398-9995.2003.00336.x
  37. BrkljacicNGracinSPrkacinI. Stevens-Johnson syndrome as an unusual adverse effect of azithromycin. Acta Dermatovenerol Croat. 2006; 14(1): 40-45
  38. PavlosRMallalSOstrovDPompeuYPhillipsE. Fever, Rash and systemic symptoms: understanding the role of virus and hla in severe cutaneous drug allergy. J Allergy Clin Immunol Pract. 2014; 2(1): 21-33. doi: 10.1016/j.jaip.2013.11.00510.1016/j.jaip.2013.11.005 https://doi.org/10.1016/j.jaip.2013.11.005
  39. UetaMKaniwaNSotozonaC. Independent strong association of HLA-A*02:06 and HLA-B 44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep. 2014; 4: 4862. doi: 10.1038/srep0486210.1038/srep04862 https://doi.org/10.1038/srep04862
  40. ShiYWMinFLQinB. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in southern han chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol. 2012; 111(1): 58-64. doi: 10.1111/j.1742- 7843.2012.00868.x10.1111/j.1742-7843.2012.00868.x https://doi.org/10.1111/j.1742-7843.2012.00868.x
  41. ChengCYSuSCChenCHChenWLDengSTChungWH. HLA Associations and clinical implications in T-cell-mediated drug hypersensitivity reactions: an updated review. J Immunol Res. 2014; 2014: 565320. doi: 10.1155/2014/56532010.1155/2014/565320 https://doi.org/10.1155/2014/565320
  42. PowerWJSaidmanSLZhangDS. HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 1996; 103(9): 1406-1409
  43. DaubeneyPEScopesJW. Recurrent Stevens-Johnson syndrome. J R Soc Med. 1991; 84(3): 168
  44. SuSCChungWH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins. 2014; 6(1): 194-210. doi: 10.3390/toxins601019410.3390/toxins6010194 https://doi.org/10.3390/toxins6010194
  45. AtkinsonTPBoppanaSTheosAClementsLSXiaoLWaitesK. Stevens-Johnson syndrome in a boy with macrolideresistant mycoplasma pneumoniae pneumonia. Pediatrics. 2011; 127(6): e1605-e1609. doi: 10.1542/peds.2010-262410.1542/peds.2010-2624 https://doi.org/10.1542/peds.2010-2624